DRMA · Dermata Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Gerald T. Proehl President, CEO and Chairman | ▲ Buy | Grant | 292,631 Shares held | 8/16/2026 | View profile |
| Van Hoose Kyri K. SVP, CFO | ▲ Buy | Grant | 232,463 Shares held | 8/16/2026 | View profile |
| Mary Fisher Director | ▲ Buy | Grant | 196,946 Shares held | 1/21/2025 | View profile |
| David F. Hale Director | ▲ Buy | Grant | 80,957 Shares held | 1/23/2025 | View profile |
| Wendell Wierenga Director | ▲ Buy | Grant | 62,398 Shares held | 10/6/2022 | View profile |
| Sandler Andrew Seth Director | ▲ Buy | Grant | 24,184 Shares held | 10/6/2022 | View profile |
| Bradrick Brittany Director | ▲ Buy | Grant | 23,443 Shares held | 10/6/2022 | View profile |
| Munera Maria E. Bedoya-Toro SVP, Regulatory Affairs | ▲ Buy | Open Market | 1,012 Shares held | 2/17/2026 | View profile |
| Kathleen D. Scott Chief Financial Officer | ▼ Sell | Open Market | 0 Shares held | 6/16/2026 | View profile |
Transaction History
| Gerald T. Proehl | ▲ Buy | Grant | 170,068 | — | 8/16/2026 |
| Van Hoose Kyri K. | ▲ Buy | Grant | 102,040 | — | 8/16/2026 |
| Kathleen D. Scott | ▼ Sell | Open Market | 11 | $13 | 6/16/2026 |
| Munera Maria E. Bedoya-Toro | ▲ Buy | Open Market | 1,000 | $1K | 2/17/2026 |
| Gerald T. Proehl | ▲ Buy | Grant | 490,196 | — | 12/23/2025 |
| Gerald T. Proehl | ▲ Buy | Grant | 122,549 | — | 12/23/2025 |
| Van Hoose Kyri K. | ▲ Buy | Grant | 122,549 | — | 12/23/2025 |
| David F. Hale | ▲ Buy | Grant | 78,741 | — | 1/23/2025 |
| Mary Fisher | ▲ Buy | Grant | 196,851 | — | 1/21/2025 |
| Van Hoose Kyri K. | ▲ Buy | Grant | 78,741 | — | 1/21/2025 |
| Gerald T. Proehl | ▲ Buy | Grant | 787,402 | — | 1/21/2025 |
| Sandler Andrew Seth | ▲ Buy | Grant | 10,120 | $0 | 10/6/2022 |
| Bradrick Brittany | ▲ Buy | Grant | 9,810 | $0 | 10/6/2022 |
| David F. Hale | ▲ Buy | Grant | 30,155 | $0 | 10/6/2022 |
| Mary Fisher | ▲ Buy | Grant | 9,810 | $0 | 10/6/2022 |
| Kathleen D. Scott | ▲ Buy | Grant | 11,359 | $0 | 10/6/2022 |
| Wendell Wierenga | ▲ Buy | Grant | 20,654 | $0 | 10/6/2022 |
| Sandler Andrew Seth | ▲ Buy | Grant | 8,874 | $0 | 7/7/2022 |
| Bradrick Brittany | ▲ Buy | Grant | 8,602 | $0 | 7/7/2022 |
| David F. Hale | ▲ Buy | Grant | 26,441 | $0 | 7/7/2022 |
| Kathleen D. Scott | ▲ Buy | Grant | 9,960 | $0 | 7/7/2022 |
| Wendell Wierenga | ▲ Buy | Grant | 18,110 | $0 | 7/7/2022 |
| Mary Fisher | ▲ Buy | Grant | 8,602 | $0 | 7/7/2022 |
| David F. Hale | ▲ Buy | Grant | 15,466 | $0 | 4/7/2022 |
| Bradrick Brittany | ▲ Buy | Grant | 5,031 | $0 | 4/7/2022 |
| Sandler Andrew Seth | ▲ Buy | Grant | 5,190 | $0 | 4/7/2022 |
| Wendell Wierenga | ▲ Buy | Grant | 10,593 | $0 | 4/7/2022 |
| Mary Fisher | ▲ Buy | Grant | 5,031 | $0 | 4/7/2022 |
| Kathleen D. Scott | ▲ Buy | Grant | 5,826 | $0 | 4/7/2022 |
| Gerald T. Proehl | ▲ Buy | Open Market | 20,000 | $48K | 11/23/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Dermata Reports Positive Results from Tome Cosmetic Study
Dermata Therapeutics said its Tome Foundational Treatment showed positive topline results in a cosmetic study. The study reported that more than 71% of patients had overall skin improvements at day 29. The company’s shares were active with a volume spike during the session. The stock sits near its 52‑week low and an RSI of 34.5.
Dermata Reports Positive Results from Tome Cosmetic Study. Dermata Therapeutics said its Tome Foundational Treatment showed positive topline results in a cosmetic study. The study reported that more than 71% of patients had overall skin improvements at day 29. The company’s shares were active with a volume spike during the session. The stock sits near its 52‑week low and an RSI of 34.5.